nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—lung cancer	0.13	0.512	CbGaD
Canagliflozin—ABCB1—lung cancer	0.124	0.488	CbGaD
Canagliflozin—ORM1—Gefitinib—lung cancer	0.0581	0.119	CbGbCtD
Canagliflozin—UGT1A9—Irinotecan—lung cancer	0.0421	0.0863	CbGbCtD
Canagliflozin—ORM1—Erlotinib—lung cancer	0.0344	0.0704	CbGbCtD
Canagliflozin—ALB—Gefitinib—lung cancer	0.0245	0.0501	CbGbCtD
Canagliflozin—ABCC2—Paclitaxel—lung cancer	0.0212	0.0435	CbGbCtD
Canagliflozin—ABCC2—Irinotecan—lung cancer	0.021	0.0429	CbGbCtD
Canagliflozin—ABCC2—Vinblastine—lung cancer	0.0186	0.0382	CbGbCtD
Canagliflozin—ABCC2—Cisplatin—lung cancer	0.0171	0.035	CbGbCtD
Canagliflozin—ABCC2—Etoposide—lung cancer	0.0168	0.0344	CbGbCtD
Canagliflozin—UGT2B4—pericardium—lung cancer	0.016	0.355	CbGeAlD
Canagliflozin—ABCC2—Docetaxel—lung cancer	0.0154	0.0315	CbGbCtD
Canagliflozin—ALB—Erlotinib—lung cancer	0.0145	0.0296	CbGbCtD
Canagliflozin—ABCB1—Topotecan—lung cancer	0.014	0.0287	CbGbCtD
Canagliflozin—ALB—Irinotecan—lung cancer	0.0131	0.0268	CbGbCtD
Canagliflozin—ABCB1—Gefitinib—lung cancer	0.0128	0.0262	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—lung cancer	0.0114	0.0235	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—lung cancer	0.0111	0.0227	CbGbCtD
Canagliflozin—ABCB1—Vinorelbine—lung cancer	0.00985	0.0202	CbGbCtD
Canagliflozin—CYP3A4—Topotecan—lung cancer	0.00838	0.0172	CbGbCtD
Canagliflozin—ABCB1—Crizotinib—lung cancer	0.00784	0.0161	CbGbCtD
Canagliflozin—CYP3A4—Gefitinib—lung cancer	0.00766	0.0157	CbGbCtD
Canagliflozin—ABCB1—Gemcitabine—lung cancer	0.00766	0.0157	CbGbCtD
Canagliflozin—ABCB1—Erlotinib—lung cancer	0.00756	0.0155	CbGbCtD
Canagliflozin—CYP3A4—Teniposide—lung cancer	0.00743	0.0152	CbGbCtD
Canagliflozin—ABCB1—Paclitaxel—lung cancer	0.00692	0.0142	CbGbCtD
Canagliflozin—ALB—Methotrexate—lung cancer	0.00691	0.0142	CbGbCtD
Canagliflozin—ABCB1—Irinotecan—lung cancer	0.00683	0.014	CbGbCtD
Canagliflozin—ABCB1—Vinblastine—lung cancer	0.00607	0.0124	CbGbCtD
Canagliflozin—CYP3A4—Vinorelbine—lung cancer	0.0059	0.0121	CbGbCtD
Canagliflozin—ABCB1—Cisplatin—lung cancer	0.00557	0.0114	CbGbCtD
Canagliflozin—ABCB1—Etoposide—lung cancer	0.00547	0.0112	CbGbCtD
Canagliflozin—ABCB1—Docetaxel—lung cancer	0.00501	0.0103	CbGbCtD
Canagliflozin—SLC5A1—mammary gland—lung cancer	0.00498	0.11	CbGeAlD
Canagliflozin—CYP3A4—Crizotinib—lung cancer	0.0047	0.00962	CbGbCtD
Canagliflozin—CYP3A4—Erlotinib—lung cancer	0.00453	0.00928	CbGbCtD
Canagliflozin—CYP3A4—Paclitaxel—lung cancer	0.00415	0.0085	CbGbCtD
Canagliflozin—CYP3A4—Irinotecan—lung cancer	0.00409	0.00838	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—lung cancer	0.00373	0.00764	CbGbCtD
Canagliflozin—CYP3A4—Vinblastine—lung cancer	0.00364	0.00745	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—lung cancer	0.00361	0.00741	CbGbCtD
Canagliflozin—SLC5A1—respiratory system—lung cancer	0.00332	0.0734	CbGeAlD
Canagliflozin—CYP3A4—Etoposide—lung cancer	0.00328	0.00672	CbGbCtD
Canagliflozin—CYP3A4—Docetaxel—lung cancer	0.003	0.00614	CbGbCtD
Canagliflozin—SLC5A1—epithelium—lung cancer	0.00277	0.0614	CbGeAlD
Canagliflozin—SLC5A1—bronchus—lung cancer	0.00273	0.0604	CbGeAlD
Canagliflozin—SLC5A1—trachea—lung cancer	0.00245	0.0543	CbGeAlD
Canagliflozin—SLC5A1—cardiac atrium—lung cancer	0.0023	0.051	CbGeAlD
Canagliflozin—CYP3A4—Doxorubicin—lung cancer	0.00224	0.00458	CbGbCtD
Canagliflozin—UGT2B4—cardiac atrium—lung cancer	0.00212	0.047	CbGeAlD
Canagliflozin—SLC5A1—lung—lung cancer	0.00176	0.039	CbGeAlD
Canagliflozin—Dapagliflozin—CYP2A6—lung cancer	0.00175	0.482	CrCbGaD
Canagliflozin—UGT2B4—lung—lung cancer	0.00162	0.0359	CbGeAlD
Canagliflozin—ALB—mammary gland—lung cancer	0.00145	0.032	CbGeAlD
Canagliflozin—Dapagliflozin—CYP1A1—lung cancer	0.00123	0.338	CrCbGaD
Canagliflozin—Dapagliflozin—ABCB1—lung cancer	0.000651	0.18	CrCbGaD
Canagliflozin—ORM1—bone marrow—lung cancer	0.000644	0.0143	CbGeAlD
Canagliflozin—ORM1—lung—lung cancer	0.000583	0.0129	CbGeAlD
Canagliflozin—ORM1—lymph node—lung cancer	0.000399	0.00883	CbGeAlD
Canagliflozin—ALB—lymph node—lung cancer	0.00035	0.00775	CbGeAlD
Canagliflozin—ABCC2—lymph node—lung cancer	0.000328	0.00726	CbGeAlD
Canagliflozin—ABCB1—respiratory system—lung cancer	0.000325	0.00719	CbGeAlD
Canagliflozin—ABCB1—epithelium—lung cancer	0.000271	0.00601	CbGeAlD
Canagliflozin—ABCB1—trachea—lung cancer	0.00024	0.00531	CbGeAlD
Canagliflozin—ABCB1—bone marrow—lung cancer	0.00019	0.00421	CbGeAlD
Canagliflozin—ABCB1—lung—lung cancer	0.000172	0.00382	CbGeAlD
Canagliflozin—Gastrointestinal disorder—Topotecan—lung cancer	0.000167	0.0015	CcSEcCtD
Canagliflozin—Fatigue—Topotecan—lung cancer	0.000167	0.0015	CcSEcCtD
Canagliflozin—Constipation—Topotecan—lung cancer	0.000166	0.00149	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Erlotinib—lung cancer	0.000166	0.00148	CcSEcCtD
Canagliflozin—Fatigue—Erlotinib—lung cancer	0.000165	0.00148	CcSEcCtD
Canagliflozin—Rash—Teniposide—lung cancer	0.000165	0.00148	CcSEcCtD
Canagliflozin—Dermatitis—Teniposide—lung cancer	0.000165	0.00148	CcSEcCtD
Canagliflozin—Infection—Vinorelbine—lung cancer	0.000165	0.00148	CcSEcCtD
Canagliflozin—Constipation—Erlotinib—lung cancer	0.000164	0.00147	CcSEcCtD
Canagliflozin—Erythema—Gemcitabine—lung cancer	0.000163	0.00146	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vinblastine—lung cancer	0.000163	0.00146	CcSEcCtD
Canagliflozin—Nervous system disorder—Vinorelbine—lung cancer	0.000163	0.00146	CcSEcCtD
Canagliflozin—Hyperkalaemia—Doxorubicin—lung cancer	0.000162	0.00146	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—lung cancer	0.000162	0.00145	CcSEcCtD
Canagliflozin—Skin disorder—Vinorelbine—lung cancer	0.000161	0.00144	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—lung cancer	0.00016	0.00143	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—lung cancer	0.000159	0.00143	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Topotecan—lung cancer	0.000158	0.00142	CcSEcCtD
Canagliflozin—Urinary tract disorder—Etoposide—lung cancer	0.000158	0.00142	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—lung cancer	0.000158	0.00141	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—lung cancer	0.000158	0.00141	CcSEcCtD
Canagliflozin—Abdominal pain—Vinblastine—lung cancer	0.000158	0.00141	CcSEcCtD
Canagliflozin—Urethral disorder—Etoposide—lung cancer	0.000157	0.00141	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Erlotinib—lung cancer	0.000157	0.00141	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—lung cancer	0.000156	0.0014	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—lung cancer	0.000156	0.0014	CcSEcCtD
Canagliflozin—Nausea—Teniposide—lung cancer	0.000155	0.00139	CcSEcCtD
Canagliflozin—Urinary tract disorder—Paclitaxel—lung cancer	0.000155	0.00139	CcSEcCtD
Canagliflozin—Hypotension—Vinorelbine—lung cancer	0.000155	0.00139	CcSEcCtD
Canagliflozin—Urticaria—Topotecan—lung cancer	0.000154	0.00138	CcSEcCtD
Canagliflozin—Urethral disorder—Paclitaxel—lung cancer	0.000154	0.00138	CcSEcCtD
Canagliflozin—Abdominal pain—Topotecan—lung cancer	0.000153	0.00137	CcSEcCtD
Canagliflozin—Erythema—Cisplatin—lung cancer	0.000152	0.00136	CcSEcCtD
Canagliflozin—Malnutrition—Cisplatin—lung cancer	0.000152	0.00136	CcSEcCtD
Canagliflozin—Abdominal pain—Erlotinib—lung cancer	0.000152	0.00136	CcSEcCtD
Canagliflozin—Rash maculo-papular—Doxorubicin—lung cancer	0.00015	0.00135	CcSEcCtD
Canagliflozin—Syncope—Irinotecan—lung cancer	0.00015	0.00135	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—lung cancer	0.00015	0.00135	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—lung cancer	0.00015	0.00134	CcSEcCtD
Canagliflozin—Loss of consciousness—Irinotecan—lung cancer	0.000147	0.00132	CcSEcCtD
Canagliflozin—Hypersensitivity—Vinblastine—lung cancer	0.000147	0.00132	CcSEcCtD
Canagliflozin—Angiopathy—Etoposide—lung cancer	0.000145	0.0013	CcSEcCtD
Canagliflozin—Asthenia—Vinblastine—lung cancer	0.000143	0.00128	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000143	0.00128	CcSEcCtD
Canagliflozin—Fatigue—Vinorelbine—lung cancer	0.000143	0.00128	CcSEcCtD
Canagliflozin—Hypersensitivity—Topotecan—lung cancer	0.000143	0.00128	CcSEcCtD
Canagliflozin—Angiopathy—Paclitaxel—lung cancer	0.000142	0.00128	CcSEcCtD
Canagliflozin—Constipation—Vinorelbine—lung cancer	0.000142	0.00127	CcSEcCtD
Canagliflozin—Asthenia—Topotecan—lung cancer	0.000139	0.00125	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—lung cancer	0.000138	0.00124	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000138	0.00124	CcSEcCtD
Canagliflozin—Asthenia—Erlotinib—lung cancer	0.000138	0.00123	CcSEcCtD
Canagliflozin—Pruritus—Topotecan—lung cancer	0.000137	0.00123	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—lung cancer	0.000137	0.00123	CcSEcCtD
Canagliflozin—Erythema—Paclitaxel—lung cancer	0.000137	0.00122	CcSEcCtD
Canagliflozin—Malnutrition—Paclitaxel—lung cancer	0.000137	0.00122	CcSEcCtD
Canagliflozin—Infection—Irinotecan—lung cancer	0.000136	0.00122	CcSEcCtD
Canagliflozin—Pruritus—Erlotinib—lung cancer	0.000136	0.00122	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vinorelbine—lung cancer	0.000136	0.00122	CcSEcCtD
Canagliflozin—Shock—Irinotecan—lung cancer	0.000135	0.00121	CcSEcCtD
Canagliflozin—Nervous system disorder—Irinotecan—lung cancer	0.000134	0.0012	CcSEcCtD
Canagliflozin—Infection—Gemcitabine—lung cancer	0.000132	0.00119	CcSEcCtD
Canagliflozin—Dizziness—Vinblastine—lung cancer	0.000132	0.00118	CcSEcCtD
Canagliflozin—Convulsion—Cisplatin—lung cancer	0.000132	0.00118	CcSEcCtD
Canagliflozin—Urticaria—Vinorelbine—lung cancer	0.000132	0.00118	CcSEcCtD
Canagliflozin—Urinary tract disorder—Docetaxel—lung cancer	0.000131	0.00118	CcSEcCtD
Canagliflozin—Abdominal pain—Vinorelbine—lung cancer	0.000131	0.00117	CcSEcCtD
Canagliflozin—Nervous system disorder—Gemcitabine—lung cancer	0.000131	0.00117	CcSEcCtD
Canagliflozin—Urethral disorder—Docetaxel—lung cancer	0.00013	0.00117	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—lung cancer	0.00013	0.00117	CcSEcCtD
Canagliflozin—Skin disorder—Gemcitabine—lung cancer	0.000129	0.00116	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000129	0.00115	CcSEcCtD
Canagliflozin—Dizziness—Topotecan—lung cancer	0.000128	0.00115	CcSEcCtD
Canagliflozin—Hypotension—Irinotecan—lung cancer	0.000128	0.00115	CcSEcCtD
Canagliflozin—Dizziness—Erlotinib—lung cancer	0.000127	0.00114	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—lung cancer	0.000125	0.00112	CcSEcCtD
Canagliflozin—Angioedema—Paclitaxel—lung cancer	0.000125	0.00112	CcSEcCtD
Canagliflozin—Hypotension—Gemcitabine—lung cancer	0.000124	0.00112	CcSEcCtD
Canagliflozin—Infection—Cisplatin—lung cancer	0.000123	0.00111	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—lung cancer	0.000123	0.0011	CcSEcCtD
Canagliflozin—Syncope—Paclitaxel—lung cancer	0.000123	0.0011	CcSEcCtD
Canagliflozin—Loss of consciousness—Etoposide—lung cancer	0.000122	0.0011	CcSEcCtD
Canagliflozin—Rash—Topotecan—lung cancer	0.000122	0.0011	CcSEcCtD
Canagliflozin—Hypersensitivity—Vinorelbine—lung cancer	0.000122	0.00109	CcSEcCtD
Canagliflozin—Dermatitis—Topotecan—lung cancer	0.000122	0.00109	CcSEcCtD
Canagliflozin—Nervous system disorder—Cisplatin—lung cancer	0.000122	0.00109	CcSEcCtD
Canagliflozin—Rash—Erlotinib—lung cancer	0.000121	0.00108	CcSEcCtD
Canagliflozin—Dermatitis—Erlotinib—lung cancer	0.000121	0.00108	CcSEcCtD
Canagliflozin—Convulsion—Etoposide—lung cancer	0.000121	0.00108	CcSEcCtD
Canagliflozin—Angiopathy—Docetaxel—lung cancer	0.000121	0.00108	CcSEcCtD
Canagliflozin—Skin disorder—Cisplatin—lung cancer	0.000121	0.00108	CcSEcCtD
Canagliflozin—Loss of consciousness—Paclitaxel—lung cancer	0.00012	0.00108	CcSEcCtD
Canagliflozin—Asthenia—Vinorelbine—lung cancer	0.000119	0.00107	CcSEcCtD
Canagliflozin—Nausea—Vinblastine—lung cancer	0.000119	0.00106	CcSEcCtD
Canagliflozin—Convulsion—Paclitaxel—lung cancer	0.000118	0.00106	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Irinotecan—lung cancer	0.000118	0.00106	CcSEcCtD
Canagliflozin—Fatigue—Irinotecan—lung cancer	0.000118	0.00106	CcSEcCtD
Canagliflozin—ABCB1—lymph node—lung cancer	0.000118	0.00261	CbGeAlD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000118	0.00106	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—lung cancer	0.000117	0.00105	CcSEcCtD
Canagliflozin—Pruritus—Vinorelbine—lung cancer	0.000117	0.00105	CcSEcCtD
Canagliflozin—Constipation—Irinotecan—lung cancer	0.000117	0.00105	CcSEcCtD
Canagliflozin—Hypotension—Cisplatin—lung cancer	0.000116	0.00104	CcSEcCtD
Canagliflozin—Malnutrition—Docetaxel—lung cancer	0.000116	0.00104	CcSEcCtD
Canagliflozin—Erythema—Docetaxel—lung cancer	0.000116	0.00104	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000116	0.00104	CcSEcCtD
Canagliflozin—Nausea—Topotecan—lung cancer	0.000115	0.00103	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000115	0.00103	CcSEcCtD
Canagliflozin—Fatigue—Gemcitabine—lung cancer	0.000115	0.00103	CcSEcCtD
Canagliflozin—Constipation—Gemcitabine—lung cancer	0.000114	0.00102	CcSEcCtD
Canagliflozin—Nausea—Erlotinib—lung cancer	0.000114	0.00102	CcSEcCtD
Canagliflozin—Dry mouth—Paclitaxel—lung cancer	0.000114	0.00102	CcSEcCtD
Canagliflozin—Infection—Etoposide—lung cancer	0.000113	0.00101	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—lung cancer	0.000112	0.00101	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Irinotecan—lung cancer	0.000112	0.001	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—lung cancer	0.000112	0.001	CcSEcCtD
Canagliflozin—Infection—Paclitaxel—lung cancer	0.000111	0.000993	CcSEcCtD
Canagliflozin—Skin disorder—Etoposide—lung cancer	0.00011	0.00099	CcSEcCtD
Canagliflozin—Shock—Paclitaxel—lung cancer	0.00011	0.000983	CcSEcCtD
Canagliflozin—Dizziness—Vinorelbine—lung cancer	0.00011	0.000983	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—lung cancer	0.00011	0.000983	CcSEcCtD
Canagliflozin—Nervous system disorder—Paclitaxel—lung cancer	0.000109	0.00098	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—lung cancer	0.000109	0.00098	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—lung cancer	0.000108	0.000972	CcSEcCtD
Canagliflozin—Skin disorder—Paclitaxel—lung cancer	0.000108	0.000971	CcSEcCtD
Canagliflozin—Abdominal pain—Irinotecan—lung cancer	0.000108	0.000969	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cisplatin—lung cancer	0.000107	0.000961	CcSEcCtD
Canagliflozin—Hypotension—Etoposide—lung cancer	0.000106	0.000953	CcSEcCtD
Canagliflozin—Rash—Vinorelbine—lung cancer	0.000105	0.000937	CcSEcCtD
Canagliflozin—Dermatitis—Vinorelbine—lung cancer	0.000104	0.000936	CcSEcCtD
Canagliflozin—Hypotension—Paclitaxel—lung cancer	0.000104	0.000934	CcSEcCtD
Canagliflozin—Syncope—Docetaxel—lung cancer	0.000104	0.000931	CcSEcCtD
Canagliflozin—Loss of consciousness—Docetaxel—lung cancer	0.000102	0.000912	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—lung cancer	0.000102	0.000912	CcSEcCtD
Canagliflozin—Hypersensitivity—Irinotecan—lung cancer	0.000101	0.000903	CcSEcCtD
Canagliflozin—Convulsion—Docetaxel—lung cancer	0.0001	0.000899	CcSEcCtD
Canagliflozin—Nausea—Vinorelbine—lung cancer	9.85e-05	0.000883	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Etoposide—lung cancer	9.82e-05	0.00088	CcSEcCtD
Canagliflozin—Asthenia—Irinotecan—lung cancer	9.81e-05	0.000879	CcSEcCtD
Canagliflozin—Fatigue—Etoposide—lung cancer	9.81e-05	0.000879	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	9.79e-05	0.000878	CcSEcCtD
Canagliflozin—Constipation—Etoposide—lung cancer	9.73e-05	0.000872	CcSEcCtD
Canagliflozin—Dry mouth—Docetaxel—lung cancer	9.64e-05	0.000864	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Paclitaxel—lung cancer	9.63e-05	0.000863	CcSEcCtD
Canagliflozin—Fatigue—Paclitaxel—lung cancer	9.62e-05	0.000862	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—lung cancer	9.58e-05	0.000859	CcSEcCtD
Canagliflozin—Asthenia—Gemcitabine—lung cancer	9.56e-05	0.000857	CcSEcCtD
Canagliflozin—Constipation—Paclitaxel—lung cancer	9.54e-05	0.000855	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—lung cancer	9.47e-05	0.000849	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—lung cancer	9.47e-05	0.000849	CcSEcCtD
Canagliflozin—Pruritus—Gemcitabine—lung cancer	9.42e-05	0.000845	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—lung cancer	9.4e-05	0.000843	CcSEcCtD
Canagliflozin—Infection—Docetaxel—lung cancer	9.39e-05	0.000842	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etoposide—lung cancer	9.3e-05	0.000834	CcSEcCtD
Canagliflozin—Shock—Docetaxel—lung cancer	9.3e-05	0.000834	CcSEcCtD
Canagliflozin—Nervous system disorder—Docetaxel—lung cancer	9.27e-05	0.000831	CcSEcCtD
Canagliflozin—Skin disorder—Docetaxel—lung cancer	9.18e-05	0.000823	CcSEcCtD
Canagliflozin—Hypersensitivity—Cisplatin—lung cancer	9.15e-05	0.00082	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Paclitaxel—lung cancer	9.12e-05	0.000817	CcSEcCtD
Canagliflozin—Dizziness—Irinotecan—lung cancer	9.04e-05	0.00081	CcSEcCtD
Canagliflozin—Urticaria—Etoposide—lung cancer	9.04e-05	0.00081	CcSEcCtD
Canagliflozin—Abdominal pain—Etoposide—lung cancer	8.99e-05	0.000806	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—lung cancer	8.99e-05	0.000806	CcSEcCtD
Canagliflozin—Asthenia—Cisplatin—lung cancer	8.91e-05	0.000798	CcSEcCtD
Canagliflozin—Urticaria—Paclitaxel—lung cancer	8.86e-05	0.000794	CcSEcCtD
Canagliflozin—Hypotension—Docetaxel—lung cancer	8.83e-05	0.000792	CcSEcCtD
Canagliflozin—Abdominal pain—Paclitaxel—lung cancer	8.82e-05	0.00079	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—lung cancer	8.7e-05	0.00078	CcSEcCtD
Canagliflozin—Rash—Irinotecan—lung cancer	8.62e-05	0.000773	CcSEcCtD
Canagliflozin—Dermatitis—Irinotecan—lung cancer	8.61e-05	0.000772	CcSEcCtD
Canagliflozin—Rash—Gemcitabine—lung cancer	8.4e-05	0.000753	CcSEcCtD
Canagliflozin—Dermatitis—Gemcitabine—lung cancer	8.39e-05	0.000752	CcSEcCtD
Canagliflozin—Hypersensitivity—Etoposide—lung cancer	8.38e-05	0.000751	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—lung cancer	8.35e-05	0.000748	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—lung cancer	8.35e-05	0.000748	CcSEcCtD
Canagliflozin—Hypersensitivity—Paclitaxel—lung cancer	8.22e-05	0.000736	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—lung cancer	8.2e-05	0.000735	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Docetaxel—lung cancer	8.16e-05	0.000731	CcSEcCtD
Canagliflozin—Asthenia—Etoposide—lung cancer	8.16e-05	0.000731	CcSEcCtD
Canagliflozin—Fatigue—Docetaxel—lung cancer	8.15e-05	0.00073	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—lung cancer	8.14e-05	0.00073	CcSEcCtD
Canagliflozin—Nausea—Irinotecan—lung cancer	8.12e-05	0.000728	CcSEcCtD
Canagliflozin—Constipation—Docetaxel—lung cancer	8.08e-05	0.000725	CcSEcCtD
Canagliflozin—Pruritus—Etoposide—lung cancer	8.05e-05	0.000721	CcSEcCtD
Canagliflozin—Asthenia—Paclitaxel—lung cancer	8e-05	0.000717	CcSEcCtD
Canagliflozin—Nausea—Gemcitabine—lung cancer	7.91e-05	0.000709	CcSEcCtD
Canagliflozin—Pruritus—Paclitaxel—lung cancer	7.89e-05	0.000707	CcSEcCtD
Canagliflozin—Rash—Cisplatin—lung cancer	7.83e-05	0.000702	CcSEcCtD
Canagliflozin—Dermatitis—Cisplatin—lung cancer	7.82e-05	0.000701	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Docetaxel—lung cancer	7.73e-05	0.000693	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—lung cancer	7.53e-05	0.000675	CcSEcCtD
Canagliflozin—Dizziness—Etoposide—lung cancer	7.52e-05	0.000674	CcSEcCtD
Canagliflozin—Abdominal pain—Docetaxel—lung cancer	7.47e-05	0.00067	CcSEcCtD
Canagliflozin—Dizziness—Paclitaxel—lung cancer	7.38e-05	0.000661	CcSEcCtD
Canagliflozin—Nausea—Cisplatin—lung cancer	7.37e-05	0.000661	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—lung cancer	7.23e-05	0.000648	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—lung cancer	7.23e-05	0.000648	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—lung cancer	7.23e-05	0.000648	CcSEcCtD
Canagliflozin—Rash—Etoposide—lung cancer	7.17e-05	0.000643	CcSEcCtD
Canagliflozin—Dermatitis—Etoposide—lung cancer	7.17e-05	0.000642	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	7.06e-05	0.000633	CcSEcCtD
Canagliflozin—Rash—Paclitaxel—lung cancer	7.03e-05	0.00063	CcSEcCtD
Canagliflozin—Dermatitis—Paclitaxel—lung cancer	7.03e-05	0.00063	CcSEcCtD
Canagliflozin—Hypersensitivity—Docetaxel—lung cancer	6.96e-05	0.000624	CcSEcCtD
Canagliflozin—Asthenia—Docetaxel—lung cancer	6.78e-05	0.000608	CcSEcCtD
Canagliflozin—Infection—Methotrexate—lung cancer	6.77e-05	0.000607	CcSEcCtD
Canagliflozin—Nausea—Etoposide—lung cancer	6.76e-05	0.000606	CcSEcCtD
Canagliflozin—Pruritus—Docetaxel—lung cancer	6.69e-05	0.000599	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—lung cancer	6.68e-05	0.000599	CcSEcCtD
Canagliflozin—Nausea—Paclitaxel—lung cancer	6.62e-05	0.000594	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—lung cancer	6.62e-05	0.000593	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—lung cancer	6.48e-05	0.000581	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—lung cancer	6.37e-05	0.000571	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—lung cancer	6.35e-05	0.000569	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—lung cancer	6.26e-05	0.000561	CcSEcCtD
Canagliflozin—Dizziness—Docetaxel—lung cancer	6.25e-05	0.00056	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	6.11e-05	0.000548	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—lung cancer	6.02e-05	0.000539	CcSEcCtD
Canagliflozin—Rash—Docetaxel—lung cancer	5.96e-05	0.000534	CcSEcCtD
Canagliflozin—Dermatitis—Docetaxel—lung cancer	5.95e-05	0.000534	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—lung cancer	5.88e-05	0.000527	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—lung cancer	5.87e-05	0.000526	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—lung cancer	5.86e-05	0.000525	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—lung cancer	5.8e-05	0.00052	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—lung cancer	5.79e-05	0.000519	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—lung cancer	5.73e-05	0.000514	CcSEcCtD
Canagliflozin—Nausea—Docetaxel—lung cancer	5.62e-05	0.000503	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—lung cancer	5.57e-05	0.000499	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—lung cancer	5.51e-05	0.000494	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—lung cancer	5.41e-05	0.000485	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—lung cancer	5.39e-05	0.000483	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—lung cancer	5.09e-05	0.000456	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—lung cancer	5.09e-05	0.000456	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—lung cancer	5.05e-05	0.000452	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—lung cancer	5.02e-05	0.00045	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—lung cancer	4.89e-05	0.000438	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—lung cancer	4.82e-05	0.000432	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—lung cancer	4.82e-05	0.000432	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—lung cancer	4.69e-05	0.00042	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—lung cancer	4.66e-05	0.000418	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—lung cancer	4.51e-05	0.000404	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—lung cancer	4.35e-05	0.00039	CcSEcCtD
Canagliflozin—Rash—Methotrexate—lung cancer	4.3e-05	0.000385	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—lung cancer	4.29e-05	0.000385	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—lung cancer	4.23e-05	0.000379	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—lung cancer	4.17e-05	0.000374	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—lung cancer	4.05e-05	0.000363	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—lung cancer	3.9e-05	0.00035	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—lung cancer	3.72e-05	0.000333	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—lung cancer	3.72e-05	0.000333	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—lung cancer	3.5e-05	0.000314	CcSEcCtD
Canagliflozin—CYP3A4—Metabolism—AZIN2—lung cancer	1.17e-05	0.000119	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SDC4—lung cancer	1.16e-05	0.000118	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM2—lung cancer	1.15e-05	0.000117	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CNDP2—lung cancer	1.15e-05	0.000117	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—lung cancer	1.14e-05	0.000116	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—lung cancer	1.14e-05	0.000116	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—lung cancer	1.14e-05	0.000116	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—lung cancer	1.13e-05	0.000115	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP2E1—lung cancer	1.12e-05	0.000114	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTMR3—lung cancer	1.12e-05	0.000114	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—lung cancer	1.11e-05	0.000113	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NQO1—lung cancer	1.11e-05	0.000113	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—lung cancer	1.1e-05	0.000112	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PGAM1—lung cancer	1.09e-05	0.000111	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—lung cancer	1.09e-05	0.000111	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—lung cancer	1.09e-05	0.000111	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.09e-05	0.000111	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—EP300—lung cancer	1.08e-05	0.00011	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.08e-05	0.00011	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—lung cancer	1.07e-05	0.000109	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—lung cancer	1.07e-05	0.000108	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—RRM1—lung cancer	1.06e-05	0.000108	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTA3—lung cancer	1.06e-05	0.000108	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2A7—lung cancer	1.04e-05	0.000106	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—lung cancer	1.03e-05	0.000105	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—RAF1—lung cancer	1.03e-05	0.000105	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—lung cancer	1.03e-05	0.000105	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—lung cancer	1.03e-05	0.000105	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—lung cancer	1.03e-05	0.000105	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SDC4—lung cancer	1.02e-05	0.000104	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—AVP—lung cancer	1.01e-05	0.000103	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—lung cancer	1.01e-05	0.000102	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—lung cancer	1.01e-05	0.000102	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—STK11—lung cancer	1e-05	0.000102	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—B4GALT5—lung cancer	9.96e-06	0.000101	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ATP5H—lung cancer	9.96e-06	0.000101	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—POMC—lung cancer	9.93e-06	0.000101	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	9.83e-06	0.0001	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—lung cancer	9.79e-06	9.96e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SRC—lung cancer	9.71e-06	9.88e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTA4—lung cancer	9.69e-06	9.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	9.56e-06	9.73e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	9.47e-06	9.64e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—lung cancer	9.46e-06	9.63e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTA2—lung cancer	9.44e-06	9.62e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	9.38e-06	9.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MMP1—lung cancer	9.33e-06	9.5e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	9.31e-06	9.48e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—RRM1—lung cancer	9.28e-06	9.45e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA3—lung cancer	9.28e-06	9.45e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTP1—lung cancer	9.25e-06	9.42e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTA1—lung cancer	9.11e-06	9.28e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCC3—lung cancer	9.01e-06	9.17e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CAT—lung cancer	9e-06	9.16e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—lung cancer	8.95e-06	9.11e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK3—lung cancer	8.94e-06	9.11e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—APOA1—lung cancer	8.93e-06	9.09e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLBD1—lung cancer	8.88e-06	9.04e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AVP—lung cancer	8.85e-06	9.01e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	8.81e-06	8.97e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—lung cancer	8.75e-06	8.91e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—B4GALT5—lung cancer	8.73e-06	8.89e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKR1C1—lung cancer	8.73e-06	8.88e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMS—lung cancer	8.6e-06	8.75e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	8.57e-06	8.72e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—lung cancer	8.5e-06	8.65e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA4—lung cancer	8.49e-06	8.64e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—UGT1A1—lung cancer	8.47e-06	8.62e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—lung cancer	8.43e-06	8.58e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—lung cancer	8.43e-06	8.58e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	8.38e-06	8.53e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA2—lung cancer	8.27e-06	8.42e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GNG11—lung cancer	8.17e-06	8.32e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—lung cancer	8.15e-06	8.3e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOA1—lung cancer	8.13e-06	8.27e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HSD17B10—lung cancer	8.12e-06	8.27e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1A1—lung cancer	8.06e-06	8.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EGF—lung cancer	8.06e-06	8.2e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ERCC2—lung cancer	7.99e-06	8.14e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA1—lung cancer	7.98e-06	8.13e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—lung cancer	7.96e-06	8.11e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	7.91e-06	8.06e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCC3—lung cancer	7.89e-06	8.04e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDOA—lung cancer	7.78e-06	7.92e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—APOA1—lung cancer	7.73e-06	7.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKR1C1—lung cancer	7.65e-06	7.78e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CREBBP—lung cancer	7.56e-06	7.69e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOA3—lung cancer	7.55e-06	7.69e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CKB—lung cancer	7.55e-06	7.68e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—UGT1A1—lung cancer	7.42e-06	7.56e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	7.42e-06	7.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—lung cancer	7.38e-06	7.52e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCG2—lung cancer	7.34e-06	7.48e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADCY1—lung cancer	7.34e-06	7.48e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	7.27e-06	7.4e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HPGDS—lung cancer	7.2e-06	7.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO2—lung cancer	7.2e-06	7.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CD—lung cancer	7.16e-06	7.29e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPP2R1B—lung cancer	7.16e-06	7.29e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GNG11—lung cancer	7.16e-06	7.29e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CNDP2—lung cancer	7.1e-06	7.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM2—lung cancer	7.1e-06	7.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—POMC—lung cancer	7.06e-06	7.19e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	7.03e-06	7.16e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—lung cancer	6.99e-06	7.11e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOA1—lung cancer	6.91e-06	7.04e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GCLC—lung cancer	6.91e-06	7.03e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2A6—lung cancer	6.91e-06	7.03e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTMR3—lung cancer	6.9e-06	7.03e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	6.88e-06	7e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDOA—lung cancer	6.81e-06	6.94e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—APOA1—lung cancer	6.77e-06	6.89e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PGAM1—lung cancer	6.73e-06	6.85e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	6.62e-06	6.74e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOA3—lung cancer	6.62e-06	6.73e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO1—lung cancer	6.55e-06	6.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CREBBP—lung cancer	6.54e-06	6.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	6.52e-06	6.64e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—lung cancer	6.51e-06	6.62e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCG2—lung cancer	6.44e-06	6.55e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADCY1—lung cancer	6.44e-06	6.55e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2A7—lung cancer	6.42e-06	6.53e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAF1—lung cancer	6.4e-06	6.51e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO2—lung cancer	6.31e-06	6.43e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—lung cancer	6.31e-06	6.43e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HPGDS—lung cancer	6.31e-06	6.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SDC4—lung cancer	6.28e-06	6.39e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPP2R1B—lung cancer	6.27e-06	6.38e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CB—lung cancer	6.24e-06	6.36e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—lung cancer	6.12e-06	6.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GCLC—lung cancer	6.05e-06	6.16e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2A6—lung cancer	6.05e-06	6.16e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—lung cancer	6.03e-06	6.14e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—POMC—lung cancer	6.01e-06	6.12e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	5.94e-06	6.05e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2E1—lung cancer	5.87e-06	5.98e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CREBBP—lung cancer	5.85e-06	5.96e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NQO1—lung cancer	5.81e-06	5.91e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO1—lung cancer	5.74e-06	5.84e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—lung cancer	5.73e-06	5.84e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	5.73e-06	5.83e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—RRM1—lung cancer	5.72e-06	5.82e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA3—lung cancer	5.72e-06	5.82e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	5.68e-06	5.79e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	5.63e-06	5.73e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CD—lung cancer	5.55e-06	5.65e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—RAF1—lung cancer	5.54e-06	5.64e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—lung cancer	5.48e-06	5.58e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—B4GALT5—lung cancer	5.38e-06	5.48e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	5.36e-06	5.46e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—STK11—lung cancer	5.23e-06	5.33e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA4—lung cancer	5.23e-06	5.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EP300—lung cancer	5.15e-06	5.24e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2E1—lung cancer	5.14e-06	5.24e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA2—lung cancer	5.1e-06	5.19e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NQO1—lung cancer	5.09e-06	5.18e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SRC—lung cancer	5e-06	5.09e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA1—lung cancer	4.92e-06	5.01e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—lung cancer	4.91e-06	5e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—lung cancer	4.87e-06	4.96e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCC3—lung cancer	4.86e-06	4.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	4.85e-06	4.94e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—lung cancer	4.84e-06	4.93e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CB—lung cancer	4.84e-06	4.92e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NRAS—lung cancer	4.81e-06	4.9e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—lung cancer	4.79e-06	4.88e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAT—lung cancer	4.71e-06	4.8e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKR1C1—lung cancer	4.71e-06	4.8e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—EP300—lung cancer	4.68e-06	4.77e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK3—lung cancer	4.61e-06	4.69e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—STK11—lung cancer	4.59e-06	4.67e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—lung cancer	4.58e-06	4.67e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UGT1A1—lung cancer	4.57e-06	4.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMS—lung cancer	4.5e-06	4.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—lung cancer	4.45e-06	4.53e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GNG11—lung cancer	4.41e-06	4.49e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—lung cancer	4.24e-06	4.32e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1A1—lung cancer	4.22e-06	4.29e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDOA—lung cancer	4.2e-06	4.27e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ERCC2—lung cancer	4.18e-06	4.26e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—lung cancer	4.18e-06	4.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—lung cancer	4.14e-06	4.22e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAT—lung cancer	4.13e-06	4.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOA3—lung cancer	4.08e-06	4.15e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—EP300—lung cancer	3.98e-06	4.06e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADCY1—lung cancer	3.96e-06	4.04e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCG2—lung cancer	3.96e-06	4.04e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMS—lung cancer	3.94e-06	4.02e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—lung cancer	3.9e-06	3.97e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO2—lung cancer	3.89e-06	3.96e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HPGDS—lung cancer	3.89e-06	3.96e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPP2R1B—lung cancer	3.86e-06	3.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—lung cancer	3.81e-06	3.88e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—lung cancer	3.77e-06	3.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCLC—lung cancer	3.73e-06	3.8e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2A6—lung cancer	3.73e-06	3.8e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1A1—lung cancer	3.7e-06	3.76e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—lung cancer	3.68e-06	3.75e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ERCC2—lung cancer	3.67e-06	3.73e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOA1—lung cancer	3.62e-06	3.68e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO1—lung cancer	3.53e-06	3.6e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—lung cancer	3.52e-06	3.59e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.47e-06	3.53e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—lung cancer	3.3e-06	3.36e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA1—lung cancer	3.17e-06	3.23e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2E1—lung cancer	3.17e-06	3.23e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—POMC—lung cancer	3.15e-06	3.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NQO1—lung cancer	3.13e-06	3.19e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—lung cancer	3.11e-06	3.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CREBBP—lung cancer	3.06e-06	3.12e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—lung cancer	2.95e-06	3e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CD—lung cancer	2.9e-06	2.96e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—lung cancer	2.89e-06	2.95e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—STK11—lung cancer	2.83e-06	2.88e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—POMC—lung cancer	2.76e-06	2.81e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CREBBP—lung cancer	2.68e-06	2.73e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—lung cancer	2.61e-06	2.66e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CD—lung cancer	2.54e-06	2.59e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAT—lung cancer	2.54e-06	2.59e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CB—lung cancer	2.53e-06	2.58e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—lung cancer	2.51e-06	2.56e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—lung cancer	2.51e-06	2.55e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—lung cancer	2.47e-06	2.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMS—lung cancer	2.43e-06	2.47e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—lung cancer	2.41e-06	2.45e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—lung cancer	2.4e-06	2.45e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1A1—lung cancer	2.28e-06	2.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ERCC2—lung cancer	2.26e-06	2.3e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CB—lung cancer	2.22e-06	2.26e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—lung cancer	2.2e-06	2.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—lung cancer	2.19e-06	2.23e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—EP300—lung cancer	2.09e-06	2.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA1—lung cancer	1.95e-06	1.99e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—lung cancer	1.92e-06	1.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—EP300—lung cancer	1.83e-06	1.86e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—lung cancer	1.78e-06	1.82e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—POMC—lung cancer	1.7e-06	1.73e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CREBBP—lung cancer	1.65e-06	1.68e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CD—lung cancer	1.57e-06	1.6e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—lung cancer	1.55e-06	1.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—lung cancer	1.54e-06	1.57e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CB—lung cancer	1.37e-06	1.39e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—lung cancer	1.35e-06	1.38e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—lung cancer	1.35e-06	1.38e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—lung cancer	1.26e-06	1.28e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—lung cancer	1.18e-06	1.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—EP300—lung cancer	1.13e-06	1.15e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—lung cancer	1.1e-06	1.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—lung cancer	8.33e-07	8.48e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—lung cancer	6.81e-07	6.93e-06	CbGpPWpGaD
